CA
NMRA icon

CoreCap Advisors’s Neumora Therapeutics NMRA Stock Holding History

CoreCap Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-57
Closed -$57 – 3071
2025
Q1 		$57 Buy
+57
New +$98 ﹤0.01% 3081

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

CoreCap Advisors's NMRA Position: Q2 2025 in Review

CoreCap Advisors sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 57 shares — an estimated $57 sold.

CoreCap Advisors first reported a position in NMRA in Q1 2025 and held it in 1 quarter. The position peaked at $57 in Q1 2025. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

  • CoreCap Advisors reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 57 Neumora Therapeutics shares in Q2 2025, an estimated $57.
  • CoreCap Advisors first reported a position in Neumora Therapeutics in Q1 2025 and held it in 1 quarter.
  • CoreCap Advisors's Neumora Therapeutics position peaked at $57 in Q1 2025.
  • 98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.